245 related articles for article (PubMed ID: 30048710)
1. Generation of Fabry cardiomyopathy model for drug screening using induced pluripotent stem cell-derived cardiomyocytes from a female Fabry patient.
Kuramoto Y; Naito AT; Tojo H; Sakai T; Ito M; Shibamoto M; Nakagawa A; Higo T; Okada K; Yamaguchi T; Lee JK; Miyagawa S; Sawa Y; Sakata Y; Komuro I
J Mol Cell Cardiol; 2018 Aug; 121():256-265. PubMed ID: 30048710
[TBL] [Abstract][Full Text] [Related]
2. Interleukin-18 deteriorates Fabry cardiomyopathy and contributes to the development of left ventricular hypertrophy in Fabry patients with GLA IVS4+919 G>A mutation.
Chien Y; Chien CS; Chiang HC; Huang WL; Chou SJ; Chang WC; Chang YL; Leu HB; Chen KH; Wang KL; Lai YH; Liu YY; Lu KH; Li HY; Sung YJ; Jong YJ; Chen YJ; Chen CH; Yu WC
Oncotarget; 2016 Dec; 7(52):87161-87179. PubMed ID: 27888626
[TBL] [Abstract][Full Text] [Related]
3. Glucosylceramide synthase inhibition with lucerastat lowers globotriaosylceramide and lysosome staining in cultured fibroblasts from Fabry patients with different mutation types.
Welford RWD; Mühlemann A; Garzotti M; Rickert V; Groenen PMA; Morand O; Üçeyler N; Probst MR
Hum Mol Genet; 2018 Oct; 27(19):3392-3403. PubMed ID: 29982630
[TBL] [Abstract][Full Text] [Related]
4. GLA-modified RNA treatment lowers GB3 levels in iPSC-derived cardiomyocytes from Fabry-affected individuals.
Ter Huurne M; Parker BL; Liu NQ; Qian EL; Vivien C; Karavendzas K; Mills RJ; Saville JT; Abu-Bonsrah D; Wise AF; Hudson JE; Talbot AS; Finn PF; Martini PGV; Fuller M; Ricardo SD; Watt KI; Nicholls KM; Porrello ER; Elliott DA
Am J Hum Genet; 2023 Sep; 110(9):1600-1605. PubMed ID: 37607539
[TBL] [Abstract][Full Text] [Related]
5. Generation of
Song HY; Chien CS; Yarmishyn AA; Chou SJ; Yang YP; Wang ML; Wang CY; Leu HB; Yu WC; Chang YL; Chiou SH
Cells; 2019 Apr; 8(4):. PubMed ID: 30965672
[TBL] [Abstract][Full Text] [Related]
6. Distributions of Globotriaosylceramide Isoforms, and Globotriaosylsphingosine and Its Analogues in an α-Galactosidase A Knockout Mouse, a Model of Fabry Disease.
Sueoka H; Aoki M; Tsukimura T; Togawa T; Sakuraba H
PLoS One; 2015; 10(12):e0144958. PubMed ID: 26661087
[TBL] [Abstract][Full Text] [Related]
7. Energy utilization of induced pluripotent stem cell-derived cardiomyocyte in Fabry disease.
Chou SJ; Yu WC; Chang YL; Chen WY; Chang WC; Chien Y; Yen JC; Liu YY; Chen SJ; Wang CY; Chen YH; Niu DM; Lin SJ; Chen JW; Chiou SH; Leu HB
Int J Cardiol; 2017 Apr; 232():255-263. PubMed ID: 28082092
[TBL] [Abstract][Full Text] [Related]
8. Familial hypertrophic obstructive cardiomyopathy with the GLA E66Q mutation and zebra body.
Oikawa M; Sakamoto N; Kobayashi A; Suzuki S; Yoshihisa A; Yamaki T; Nakazato K; Suzuki H; Saitoh S; Kiko Y; Nakano H; Hayashi T; Kimura A; Takeishi Y
BMC Cardiovasc Disord; 2016 May; 16():83. PubMed ID: 27160240
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of Arachidonate 12/15-Lipoxygenase Improves α-Galactosidase Efficacy in iPSC-Derived Cardiomyocytes from Fabry Patients.
Chien Y; Chou SJ; Chang YL; Leu HB; Yang YP; Tsai PH; Lai YH; Chen KH; Chang WC; Sung SH; Yu WC
Int J Mol Sci; 2018 May; 19(5):. PubMed ID: 29772700
[TBL] [Abstract][Full Text] [Related]
10. Characterization of cellular phenotypes in neurons derived from induced pluripotent stem cells of male patients with Fabry disease.
Miyajima T; Saito R; Yanagisawa H; Igarashi M; Wu C; Iwamoto T; Eto Y
J Inherit Metab Dis; 2023 Jan; 46(1):143-152. PubMed ID: 36220782
[TBL] [Abstract][Full Text] [Related]
11. Enhanced thrombospondin-1 causes dysfunction of vascular endothelial cells derived from Fabry disease-induced pluripotent stem cells.
Do HS; Park SW; Im I; Seo D; Yoo HW; Go H; Kim YH; Koh GY; Lee BH; Han YM
EBioMedicine; 2020 Feb; 52():102633. PubMed ID: 31981984
[TBL] [Abstract][Full Text] [Related]
12. Familial globotriaosylceramide-associated cardiomyopathy mimicking Fabry disease.
Apelland T; Gude E; Strøm EH; Gullestad L; Eiklid KL; Månsson JE; Reinholt FP; Houge G; Dahl CP; Almaas VM; Heiberg A
Heart; 2014 Nov; 100(22):1793-8. PubMed ID: 25031264
[TBL] [Abstract][Full Text] [Related]
13. Is it Fabry disease?
Schiffmann R; Fuller M; Clarke LA; Aerts JM
Genet Med; 2016 Dec; 18(12):1181-1185. PubMed ID: 27195818
[TBL] [Abstract][Full Text] [Related]
14. Generation of a GLA knock-out human-induced pluripotent stem cell line, KSBCi002-A-1, using CRISPR/Cas9.
Kim YK; Yu JH; Min SH; Park SW
Stem Cell Res; 2020 Jan; 42():101676. PubMed ID: 31841972
[TBL] [Abstract][Full Text] [Related]
15. Generation of human induced pluripotent stem cell line MHHi029-A from a male Fabry disease patient carrying c.959A > T mutation.
Jahn C; Juchem M; Sonnenschein K; Gietz A; Buchegger T; Lachmann N; Göhring G; Behrens YL; Bär C; Thum T; Hoepfner J
Stem Cell Res; 2024 Jun; 77():103404. PubMed ID: 38552356
[TBL] [Abstract][Full Text] [Related]
16. Risk of death in heart disease is associated with elevated urinary globotriaosylceramide.
Schiffmann R; Forni S; Swift C; Brignol N; Wu X; Lockhart DJ; Blankenship D; Wang X; Grayburn PA; Taylor MR; Lowes BD; Fuller M; Benjamin ER; Sweetman L
J Am Heart Assoc; 2014 Feb; 3(1):e000394. PubMed ID: 24496231
[TBL] [Abstract][Full Text] [Related]
17. Effective clearance of GL-3 in a human iPSC-derived cardiomyocyte model of Fabry disease.
Itier JM; Ret G; Viale S; Sweet L; Bangari D; Caron A; Le-Gall F; Bénichou B; Leonard J; Deleuze JF; Orsini C
J Inherit Metab Dis; 2014 Nov; 37(6):1013-22. PubMed ID: 24850378
[TBL] [Abstract][Full Text] [Related]
18. A symptomatic Fabry disease mouse model generated by inducing globotriaosylceramide synthesis.
Taguchi A; Maruyama H; Nameta M; Yamamoto T; Matsuda J; Kulkarni AB; Yoshioka H; Ishii S
Biochem J; 2013 Dec; 456(3):373-83. PubMed ID: 24094090
[TBL] [Abstract][Full Text] [Related]
19. Correlation of X chromosome inactivation with clinical presentation of Fabry disease in a case report.
Rodríguez Doyágüez P; Furlano M; Ars Criach E; Arce Y; Guirado L; Torra Balcells R
Nefrologia (Engl Ed); 2023 Dec; 43 Suppl 2():91-95. PubMed ID: 38278716
[TBL] [Abstract][Full Text] [Related]
20. Differences in cleavage of globotriaosylceramide and its derivatives accumulated in organs of young Fabry mice following enzyme replacement therapy.
Kodama T; Tsukimura T; Kawashima I; Sato A; Sakuraba H; Togawa T
Mol Genet Metab; 2017; 120(1-2):116-120. PubMed ID: 27756537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
